Insilico Medicine, a clinical stage biotech company powered by generative AI, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases.
我们正在追踪 Insilico Medicine 的市场扩张
最近 90 天内有 16 个信号。
Insilico Medicine 的国际扩张与竞争对手的对比情况
Insilico Medicine你条形图显示所对比公司之间的相对规模。
列5| 公司 | 市场 | 新市场 | 势头 | 活动 | 扩张评分 |
|---|---|---|---|---|---|
 Insilico Medicine你 | 0 | 0 | — | 0 | 0 |
Machine Learning Engineer
查看职位Abu Dhabi, Abu Dhabi Emirate, United Arab Emirates · 上个月
Business Development Manager - AI Platform Technologies
查看职位Tokyo, Japan · 2个月前
Clinical Project Manager (Oncology) Consultant
查看职位United States · 2个月前
Most frontier models continue to miss the mark on critical ADMET and toxicity tasks. Domain expertise isn't solved by prompt tuning alone, it requires specialized training.Through our partnership with Liquid AI, we’ve utilized the MMAI Gym for Science to transform the LFM2-2.6B model into a drug discovery powerhouse. Despite its small footprint, it is now delivering State-of-the-Art (SOTA) results that rival or surpass models ten times its size.We’re ready to help you integrate these models dire ...
进行中
Through our partnership with Liquid AI, we’ve utilized the MMAI Gym for Science to transform the LFM2-2.6B model into a drug discovery powerhouse. Despite its small footprint, it is now delivering State-of-the-Art (SOTA) results that rival or surpass models ten times its size.
进行中
Through our partnership with Liquid AI, we’ve utilized the MMAI Gym for Science to transform the LFM2-2.6B model into a drug discovery powerhouse. Despite its small footprint, it is now delivering State-of-the-Art (SOTA) results that rival or surpass models ten times its size.
进行中Insilico Medicine成立业界首个长寿委员会,由礼来公司Andrew Adams领导,监督AI驱动的衰老研究和药物发现,针对生物衰老过程和健康寿命延长。
英矽智能成立行业首个长寿委员会,为AI驱动的衰老研究和药物发现提供科学监督,专注于同时针对衰老和疾病机制的双重用途靶点开发。
英矽智能提名ISM0387为第30款AI驱动临床前候选药物,也是首个在阿联酋研发的候选药物,针对胶质母细胞瘤的MTA协同PRMT5抑制剂,利用生成式AI平台12个月内完成。
解锁已验证邮箱与直拨电话
免费 · 无需信用卡
关于 Insilico Medicine 的业务、市场和增长信号的快速解答。
